Fernando Bril focused on MASLD patients with fibrosis and analyzed LCAT mass on the basis of His-apoAI binding proteomics, and Janac et al. focused on lipid disorders in MASLD patients and measured the decrease in endogenous substrates (plasma FC) to indicate LCAT activity. Here, LCAT is linked to metabolic dysfunction-associated steatotic liver disease.